Trial Profile
A phase I/II study of Cetuximab combined with irinotecan and S-1 as first line therapy in metastatic colorectal cancer patients with KRAS wild type
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 13 May 2016
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Gimeracil/oteracil/tegafur (Primary) ; Irinotecan (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- 18 Apr 2016 Status changed from recruiting to completed.
- 31 Jan 2013 New trial record